JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Time to Castration Resistance is Associated With Overall Survival Even After the Achievement of Castration Resistance in Metastatic Prostate Cancer

  • 0Department of Urology, Teikyo University Chiba Medical Center, Chiba, Japan.
The Prostate +

|

January 8, 2025

|

January 8, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Time to castration resistance is a key prognostic factor for metastatic prostate cancer survival, even after treatment resistance develops. This finding highlights its role as a biomarker for androgen receptor signaling activity.

Area Of Science

  • Oncology
  • Prostate Cancer Research
  • Clinical Biomarkers

Background

  • Metastatic castration-sensitive prostate cancer (mCSPC) patients show variable survival in real-world settings.
  • Some mCSPC patients with low tumor burden and no visceral metastasis still experience poor outcomes.
  • Androgen receptor (AR) signaling remains a critical therapeutic target, even in castration-resistant disease.

Purpose Of The Study

  • To investigate novel prognostic factors for metastatic castration-sensitive prostate cancer.
  • To specifically assess the prognostic value of time to castration resistance (TTR) in mCSPC.
  • To evaluate TTR as a potential biomarker for AR signaling activity.

Main Methods

  • Retrospective analysis of 261 patients with newly diagnosed mCSPC.
  • Data collected from January 2007 to December 2023 at a single institution.
  • Statistical association analysis between clinical factors and overall survival (OS).

Main Results

  • Median OS was 60.7 months; median TTR was 13.1 months.
  • 158 out of 261 patients developed castration-resistant prostate cancer (CRPC).
  • Shorter TTR, distant lymph node metastasis, ISUP grade group 5, and older age correlated with shorter OS in CRPC patients.
  • Shorter TTR independently predicted shorter OS, irrespective of tumor burden or post-CRPC status.

Conclusions

  • Time to castration resistance serves as a prognostic biomarker in mCSPC.
  • TTR indicates persistent androgen receptor signaling activity, even after castration resistance is achieved.
  • TTR is a valuable prognostic indicator regardless of initial tumor burden.

Keywords: